Health
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trialFirst US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health prioritiesWegovy® HD complements Wegovy® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reductionNovo Nordisk expects to launch Wegovy® HD in the US in
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"First US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health priorities","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy® HD complements Wegovy® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reduction","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Novo Nordisk expects to launch Wegovy® HD in the US in April 2026","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":511,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 19 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.","length":454,"tagName":"p"},{"type":"text","content":"The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%1. In both trials, the well-known safety a...